Skip to main content

Table 1 Baseline clinical and pathologic characteristics of discovery cohort

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

Variable

No response

Response

OR (95% CI)a

N (%)

10 (19.6)

41 (80.4)

Age (year)

38.2 ± 21.9

37.8 ± 19.4

1.001 (0.97–1.04)

Gender (%) male

6 (60.0)

26 (63.4)

1.15 (0.28–4.77)

MAP (mmHg)

99.6 ± 17.6

90.3 ± 18.5

1.05 (0.99–1.12)

BMI (kg/m2)

26.2 ± 5.5

24.4 ± 5.1

1.07 (0.93–1.22)

Ln(Pro) (g/24 h)

2.1 ± 0.4

2.0 ± 0.4

1.53 (0.30–7.79)

Albumin (g/L)

17.0 ± 6.7

14.3 ± 5.5

1.10 (0.97–1.25)

eGFR (mL/min/1.73 m2)

103.5 ± 20.2

102.3 ± 30.6

1.003 (0.97–1.03)

TG (mmol/L)

3.1 ± 2.2

3.2 ± 1.8

0.98 (0.66–1.47)

TC (mmol/L)

8.5 ± 3.8

10.2 ± 3.1

0.79 (0.60–1.05)

Ln(MAU) (mg/L)

7.9 ± 1.3

8.5 ± 1.2

0.62 (0.34–1.13)

Ln(ORM) (mg/g Cr)

5.0 ± 1.2

5.6 ± 1.0

0.55 (0.27–1.15)

Ln(RBP) (mg/L)

− 1.1 ± 1.7

− 0.7 ± 1.7

0.85 (0.55–1.33)

Ln(β2-MG) (ug/L)

6.6 ± 1.8

5.7 ± 1.4

1.89 (1.02–3.53)#

Ln(α1-MG) (mg/dL)

1.6 ± 0.9

1.3 ± 1.0

1.40 (0.63–3.04)

Pathology

   

 FSGS (%)

5 (45.5)

6 (54.5)

5.83 (1.29–26.46)*

 MCD (%)

5 (12.5)

35 (87.5)

0.17 (0.04–0.78)*

  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; MAU: microalbumin; ORM: orosomucoid; RBP: retinol binding protein; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin; FSGS: focal segmental glomerulosclerosis; IgAN: Immunoglobulin A nephropathy; MCD: minimal change disease
  2. a Clinical characteristics are adjusted by age and gender
  3. *P < 0.05, #P < 0.01